Combination therapies using metformin and/or valproic acid in prostate cancer: Possible mechanistic interactions

    Research output: Contribution to journalReview articlepeer-review

    2 Citations (Scopus)

    Abstract

    Prostate cancer (PCa) is the most frequent cancer in men. The evolution from local PCa to castration-resistant PCa, an end-stage of disease, is often associated with changes in genes such as p53, androgen receptor, PTEN, and ETS gene fusion products. Evidence is accumulating that repurposing of metformin (MET) and valproic acid (VPA) either when used alone, or in combination, with another therapy, could potentially play a role in slowing down PCa progression. This review provides an overview of the application of MET and VPA, both alone and in combination with other drugs for PCa treatment, correlates the responses to these drugs with common molecular changes in PCa, and then describes the potential for combined MET and VPA as a systemic therapy for prostate cancer, based on potential interacting mechanisms.

    Original languageEnglish
    Pages (from-to)368-381
    Number of pages14
    JournalCURRENT CANCER DRUG TARGETS
    Volume19
    Issue number5
    DOIs
    Publication statusPublished - 2019

    Keywords

    • AMPK
    • Androgen signaling pathway
    • Chemotherapy
    • ERG overexpression
    • ETS gene fusion
    • Histone deacetylase inhibitor
    • Metformin
    • mTOR
    • p53 protein
    • Prostate cancer
    • PTEN
    • Valproic acid

    Fingerprint Dive into the research topics of 'Combination therapies using metformin and/or valproic acid in prostate cancer: Possible mechanistic interactions'. Together they form a unique fingerprint.

    Cite this